Allogene Therapeutics Stock (NASDAQ:ALLO)
Previous Close
$2.72
52W Range
$2.01 - $5.78
50D Avg
$2.69
200D Avg
$3.18
Market Cap
$627.34M
Avg Vol (3M)
$1.89M
Beta
0.83
Div Yield
-
ALLO Company Profile
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
ALLO Performance
Peer Comparison
Ticker | Company |
---|---|
SANA | Sana Biotechnology, Inc. |
VECT | VectivBio Holding AG |
BPMC | Blueprint Medicines Corporation |
IPSC | Century Therapeutics, Inc. |
NTLA | Intellia Therapeutics, Inc. |
EDIT | Editas Medicine, Inc. |
PRME | Prime Medicine, Inc. |
VERV | Verve Therapeutics, Inc. |
RLAY | Relay Therapeutics, Inc. |
GTHX | G1 Therapeutics, Inc. |
HRTX | Heron Therapeutics, Inc. |
SGMO | Sangamo Therapeutics, Inc. |
CRBU | Caribou Biosciences, Inc. |
ANNX | Annexon, Inc. |
ITOS | iTeos Therapeutics, Inc. |
BEAM | Beam Therapeutics Inc. |
LIFE | aTyr Pharma, Inc. |